You are here

Matsusaka Satoshi

Affiliation
Faculty of Medicine
Official title
Professor
Career history
2015-10 -- 2018-05がん研有明病院 消化器内科 がん研究所蛋白創製研究部兼任 医長
2013-10 -- 2015-09南カリフォルニア大学 腫瘍内科 ポスドクフェロー
2012-02 -- 2013-09がん研有明病院 消化器内科 医長
2006-04 -- 2012-01がん研有明病院 化学療法科 医員
2004-04 -- 2006-03山形大学 医学部医学科環境病態医学分野 助教
2002-04 -- 2003-03神戸大学 医学系研究科機能ゲノム学分野 COE研究員
2000-04 -- 2002-03宝塚市立病院 外科 医員
1994-04 -- 2000-03兵庫医科大学 第一外科 医員
Other articles
  • Estrogen receptor-beta genetic variations and overall survival in patients with locally advanced gastric cancer.
    Y Sunakawa; S Cao; MD Berger; S Matsusaka; D Yang; Zhang ...
    Pharmacogenomics J/17(1)/pp.36-41, 2017-01
  • A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab.
    MD Berger; S Stintzing; V Heinemann; S Cao; D Yang; Y Sun...
    Clin Cancer Res/24(4)/pp.784-793, 2018-02
  • A Feasibility Study of Capecitabine and Oxaliplatin for Patients with Stage II/III Colon Cancer -ACTOR Study.
    M Suenaga; T Akiyoshi; E Shinozaki; Y Fujimoto; S Matsusa...
    Anticancer Res/17(3)/pp.e471-e488, 2018-09
  • Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.
    Clin Colorectal Cancer; Loupakis F; Yang D; Cremolini C; ...
    Clin Colorectal Cancer, 2018-05
  • Genetic variants associated with colorectal brain metastases susceptibility and survival.
    Stremitzer S; Berghoff AS; Volz NB; Zhang W; Yang D; Stin...
    Pharmacogenomics J./17(1)/pp.29-35, 2017-01
  • A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer.
    Nakayama N; Ishido K; Chin K; Nishimura K; Azuma M; Matsu...
    Gastric Cancer./20(2)/pp.350-357, 2017-03
  • Detection of KRAS Mutations in Plasma DNA Using a fully Automated Rapid Detection System in Colorectal Cancer Patients.
    Hosoya K; Matsusaka S; Kashiwada T; Suzuki K; Ureshino N;...
    Pathol Oncol Res./23(4)/pp.737-744, 2017-10
  • Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer.
    Sunakawa Y; Cao S; Volz NB; Berger MD; Yang D; Parekh A; ...
    Pharmacogenomics J./17(6)/pp.528-534, 2017-12
  • A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials.
    Sebio A; Stintzing S; Heinemann V; Sunakawa Y; Zhang W; I...
    Pharmacogenomics J./18(1)/pp.43-48, 2018-01
  • Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials.
    Berger MD; Yamauchi S; Cao S; Hanna DL; Sunakawa Y; Schir...
    Eur J Cancer./77/pp.13-20, 2017-05
  • Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients.
    Mishima Y; Matsusaka S; Chin K; Mikuniya M; Minowa S; Tak...
    Target Oncol./12(3)/pp.341-351, 2017-06
  • Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer.
    Okazaki S; Stintzing S; Sunakawa Y; Cao S; Zhang W; Yang ...
    Int J Cancer/141(6)/pp.1222-1230, 2017-09
  • Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06).
    Kimura Y; Fujii M; Masuishi T; Nishikawa K; Kunisaki C; M...
    Gastric Cancer/21(3)/pp.421-427, 2018-05
  • Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.
    Berger MD; Stintzing S; Heinemann V; Yang D; Cao S; Sunak...
    Ann Oncol/28(11)/pp.2780-2785, 2017-11
  • CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy.
    松阪 諭; Cao S Hanna DL; Hanna DL; Sunakawa Y; Ueno M; Mi...
    Pharmacogenomics J./17(6)/pp.543-550, 2017-12
  • Prognostic impact of FOXF1 polymorphisms in gastric cancer patients.
    Matsusaka S; Wu AH; Cao S; Hanna DL; Chin K; Yang D; Zhan...
    Pharmacogenomics J./18(2)/pp.262-269, 2018-04

(Last updated: 2018-09-18)